𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -3.6% S&P500 YTD: +4.1% TOTAL RETURNS (Jan 2022) Natan's portfolio: +115.2% *Benchmark: +36.3% S&P500: +58.2% MY POSITIONS: 20.2% | $TransMedics Group, Inc.(TMDX)$ 16.0% | $PDD Holdings Inc(PDD)$ 13.0% | $Robinhood(HOOD)$ 10.7% | $Meta Platforms, Inc.(META)$ 8.9% | $Alibaba(BABA)$ 7.4% | $PROCEPT BioRobotics(PRCT)$ 7.3% | $PayPal(PYPL)$ 5.5% |

MY $TransMedics Group, Inc.(TMDX)$ VALUATION MODEL PRICE TARGET: $216 --> $220 POTENTIAL UPSIDE: +116% ✅ ASSUMPTIONS: LTM Revenue: $0.605B 5Y Revenue CAGR: 23% --> 22% 2030 Profit Margin: 24% 2030 PE Ratio: 40 Shares outstanding: 0.0409B Shares dilution: 2%/year VALUATION: Q4 2030 $TMDX SHARE PRICE = 0.605 * (1.22)^5 * 0.24 * 40 / [0.0409 * (1.02)^5] = 348$ You can now choose the discount rate that you prefer, for Transmedics I want to use 12% ACTUAL PRICE: $102 FAIR VALUE: $197 PRICE TARGET (1Y): $220 POTENTIAL UPSIDE: +116% EXPECTED RETURNS: 27.8%/year DIVIDEND YIELD: - 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘐'𝘮 𝘯𝘰𝘵 𝘢 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳 and all the 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘥 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥

Q1 2026 turned out to be my second worst quarter since 2022, with a -14.5% return. With many names down 30% in just one month, it was hard to do much better. My exposure to healthcare partially protected part of the portfolio. Given the numerous opportunities, I preferred to rotate that part of the healthcare allocation into more offensive stocks in order to take advantage of the current discounts. I’m extremely confident in my allocation and, based on my fair value estimates, I believe the portfolio can deliver a 24% CAGR over the next five years, a number from which a large part of my conviction comes. For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.

$Monday.com Ltd.(MNDY)$ IS VERY UNDERVALUED 👇🏻PRICE TARGET: $230POTENTIAL UPSIDE: +59% ✅ASSUMPTIONS:LTM Revenue: $1.166B5Y Revenue CAGR: 18% 2030 Profit Margin: 20%2030 PE Ratio: 35 Shares outstanding: 0.0533BShares dilution: 0%/yearVALUATION:Q3 2030 $MNDY SHARE PRICE =1.166 * (1.18)^5 * 0.20 * 35 /[0.0533 * (1.00)^5] = 350$You can now choose the discount rate that you prefer, for Monday I want to use 11%ACTUAL PRICE: $145FAIR VALUE: $208PRICE TARGET (1Y): $230POTENTIAL UPSIDE: +59%EXPECTED RETURNS: 19.3%/yearDIVIDEND YIELD: - ImageFor SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.

Hello everyone! Today i want to share some trading ideas with you!1.These are 5 positions in my portfolio that I’d like to increase: $PROCEPT BioRobotics(PRCT)$ : a fast-growing robotic surgery company almost forgotten by the market, very undervalued. $PayPal(PYPL)$ : the business is accelerating and the valuation keeps compressing: low risk, high reward. $Meta Platforms, Inc.(META)$ : I think Mark is doing the right thing with AI spending, the market as usual is focused on the short term: good time to take advantage. $PDD Holdings Inc(PDD)$ : extremely cheap, extremely high quality business generating $15B+ FCF, there ar

𝙈𝙔 $Regeneron Pharmaceuticals(REGN)$ 𝙑𝘼𝙇𝙐𝘼𝙏𝙄𝙊𝙉 𝙈𝙊𝘿𝙀𝙇1Y TARGET: $865 --> $930POTENTIAL UPSIDE: +43% ✅"Regeneron remains my favorite large Cap biotech, Dupixent alone justify almost totally current valuation" ASSUMPTIONS:LTM Revenue: $14.248B5Y Revenue CAGR: 8%2030 Profit Margin: 35%2030 PE Ratio: 17 --> 18Shares outstanding: 107.2MShares reduction: 2%/yearVALUATION:Q3 2030 $REGN SHARE PRICE =14.248 * (1.08)^5 * 0.35 * 18 /[0.1072 * (0.98^5)] = $1361You can now choose the discount rate that you prefer, for Regeneron I want to use 10%. ACTUAL PRICE: $650FAIR VALUE: $845PRICE TARGET (1Y): $930POTENTIAL UPSIDE: +43%EXPECTED RETURNS: 15.9%/yearDIVIDEND YIELD: 0.5%Do you own REGN shares? Stock chart for Regeneron Pharmaceuticals Inc NASDAQ REGN dis

MY 5 FAVORITE STOCK OPPORTUNITIES🧵(No one is paying attention to n°5) 1) $TransMedics Group, Inc.(TMDX)$ Revolutionizing organ transplants, founder-led, stellar track record, and still cheap for its growth.Natan's fair value: $174 (+48%)Stock chart for Transmedics ($TMDX) displaying current price of 117.63 USD with 104.38 or 87.77 percent gain over past five years closed at 17 October 19:42 GMT after hours at 117.50 down 0.13 or 0.11 percent line graph showing price trend from 2023 to 2025 with time periods 1D 5D 1M 6M YTD 5Y and price scale from 0 to 200 disclaimer noted.2) $Regeneron Pharmaceuticals(REGN)$ One of the best biotechs ever.The company reinvests 40% of revenue in R&D, and excluding that,

IS UP 10% IN JUST 5 DAYS AND STILL LOOKS RIDICULOUSLY UNDERVALUED.PRICE TARGET: $118POTENTIAL UPSIDE: +57% ✅ASSUMPTIONS:LTM Revenue: $32.292B5Y Revenue CAGR: 7%2030 Profit Margin: 16%2030 PE Ratio: 18Shares outstanding: 0.977BShares reduction: 5%/yearVALUATION:Q2 2030 PYPL SHARE PRICE =32.292 * (1.07)^5 * 0.16 * 18 /[0.977 * (0.95)^5] = 173$You can now choose the discount rate that you prefer, for PayPal I want to use 10%. ACTUAL PRICE: $75 FAIR VALUE: $107PRICE TARGET: $118POTENTIAL UPSIDE: +57%EXPECTED RETURNS: 18.2%/yearDIVIDEND YIELD: - What do you think about $PayPal(PYPL)$ ? Stock price chart for PayPal Holdings Inc ticker PYPL on NASDAQ displaying price movements from February 2025 to October 2025. Current price shown as 74.61 USD with 8.07

$Alibaba(BABA)$ PRICE TARGET: $192POTENTIAL UPSIDE: +8% ✅"Alibaba remains a decent opportunity considering the accelerating growth of Cloud business but part of the upside is clearly gone" ASSUMPTIONS:LTM Revenue: $138.995B(𝘢𝘴𝘴𝘶𝘮𝘪𝘯𝘨 𝘜𝘚𝘋/𝘊𝘕𝘠 = 𝟩.𝟤𝟢) 5Y Revenue CAGR: 9%2030 Profit Margin: 17%2030 PE Ratio: 18Shares outstanding: 2.393BShares reduction: 2%/year VALUATION:Q2 2030 $BABA SHARE PRICE =138.995 * (1.09)^5 * 0.17 * 18 /[2.393 * (0.98)^5] = $303You can now choose the discount rate that you prefer, for Alibaba I want to use 12%ACTUAL PRICE: $177FAIR VALUE: $172PRICE TARGET (1Y): $192POTENTIAL UPSIDE: 8%EXPECTED RETURNS: 11.4%/yearDIVIDEND YIELD: 0.6%Are you selling your BABA shares? An orange background with a white stylized "a" logo featuring

$PayPal(PYPL)$ IS EXTREMELY UNDERVALUED!PRICE TARGET: $118POTENTIAL UPSIDE: +74% ✅"In my view, PayPal remains very undervalued, also supported by the aggressive buyback program. Margins are improving and revenue acceleration is expected in 2026" ASSUMPTIONS:LTM Revenue: $32.292B5Y Revenue CAGR: 7%2030 Profit Margin: 16%2030 PE Ratio: 18Shares outstanding: 0.977BShares reduction: 5%/yearVALUATION:Q2 2030 $PYPL SHARE PRICE =32.292 * (1.07)^5 * 0.16 * 18 /[0.977 * (0.95)^5] = 173$You can now choose the discount rate that you prefer, for PayPal I want to use a 10%ACTUAL PRICE: $68FAIR VALUE: $107PRICE TARGET: $118POTENTIAL UPSIDE: +66%EXPECTED RETURNS: 20.5%/yearDIVIDEND YIELD: - A stock chart for PayPal Holdings Inc, ticker NASDAQ: PYPL. The chart sh